Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEST MRI-based Surgical Resections for Glioblastoma
NCT06448286Phase 3Not yet recruiting
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Dec 2026
- Primary completion
- Dec 2030
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in glioblastoma (GBM) (2 arms), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoint: Progression-Free Survival at 2 years. Planned start Dec 2026; status: not yet recruiting.
02
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06448286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06448286.